These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 28124511)

  • 61. Effectiveness and safety of ledipasvir/sofosbuvir±ribavirin in the treatment of HCV infection: The real-world HARVEST study.
    Flisiak R; Łucejko M; Mazur W; Janczewska E; Berak H; Tomasiewicz K; Mozer-Lisewska I; Kozielewicz D; Gietka A; Sikorska K; Wawrzynowicz-Syczewska M; Nowak K; Zarębska-Michaluk D; Musialik J; Simon K; Garlicki A; Pleśniak R; Baka-Ćwierz B; Olszok I; Augustyniak K; Stolarz W; Białkowska J; Badurek A; Piekarska A
    Adv Med Sci; 2017 Sep; 62(2):387-392. PubMed ID: 28554119
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Three patients treated with sofosbuvir plus ledipasvir for recurrent hepatitis C after liver transplantation.
    Kawaoka T; Imamura M; Morio K; Nakamura Y; Tsuge M; Nelson Hayes C; Kawakami Y; Aikata H; Ochi H; Ishiyama K; Ohdan H; Chayama K
    Clin J Gastroenterol; 2017 Apr; 10(2):179-184. PubMed ID: 28224470
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effective Treatment of Chronic Hepatitis C Virus Infection With Ledipasvir/Sofosbuvir in 2 Teenagers With HIV Coinfection: A Brief Report.
    Pokorska-Śpiewak M; Dobrzeniecka A; Ołdakowska A; Marczyńska M
    Pediatr Infect Dis J; 2021 Dec; 40(12):1087-1089. PubMed ID: 34232923
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Open Label Study of 8 vs. 12 Weeks of Ledipasvir/Sofosbuvir in Genotype 6 Treatment Naïve or Experienced Patients.
    Nguyen MH; Trinh H; Do S; Nguyen T; Nguyen P; Henry L
    Am J Gastroenterol; 2017 Dec; 112(12):1824-1831. PubMed ID: 29087397
    [TBL] [Abstract][Full Text] [Related]  

  • 65. NS5A resistance leading to failure of 24-week therapy with sofosbuvir/ledipasvir and ribavirin for the treatment of hepatitis C genotype 1a infection in a HIV-1 co-infected patient.
    Sevastianova K; Dean J; Bannan C; Coghlan M; Farrell G; Murray C; De Gascun CF; Bergin C
    J Clin Virol; 2016 Sep; 82():66-69. PubMed ID: 27454231
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
    Doss W; Shiha G; Hassany M; Soliman R; Fouad R; Khairy M; Samir W; Hammad R; Kersey K; Jiang D; Doehle B; Knox SJ; Massetto B; McHutchison JG; Esmat G
    J Hepatol; 2015 Sep; 63(3):581-5. PubMed ID: 25937436
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study.
    Surendra M; Raju SB; Sridhar N; Vijay Kiran B; Rajesh G; Anvesh G; Raju N
    Hemodial Int; 2018 Apr; 22(2):217-221. PubMed ID: 28972699
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients.
    Eisenberger U; Guberina H; Willuweit K; Bienholz A; Kribben A; Gerken G; Witzke O; Herzer K
    Transplantation; 2017 May; 101(5):980-986. PubMed ID: 27495770
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study.
    Deterding K; Spinner CD; Schott E; Welzel TM; Gerken G; Klinker H; Spengler U; Wiegand J; Schulze Zur Wiesch J; Pathil A; Cornberg M; Umgelter A; Zöllner C; Zeuzem S; Papkalla A; Weber K; Hardtke S; von der Leyen H; Koch A; von Witzendorff D; Manns MP; Wedemeyer H;
    Lancet Infect Dis; 2017 Feb; 17(2):215-222. PubMed ID: 28029529
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT
    J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
    N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Ledipasvir/Sofosbuvir in Adolescents With Chronic Hepatitis C Genotype 4 With and Without Hematological Disorders: Virological Efficacy and Impact on Liver Stiffness.
    Makhlouf NA; Abdelmalek MO; Ibrahim ME; Abu-Faddan NH; Kheila AE; Mahmoud AA
    J Pediatric Infect Dis Soc; 2021 Feb; 10(1):7-13. PubMed ID: 32060510
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Ledipasvir/sofosbuvir with or without ribavirin for the treatment of chronic hepatitis C genotype 1: A pairwise meta-analysis.
    Ferreira VL; Assis Jarek NA; Tonin FS; Borba HH; Wiens A; Muzzillo DA; Pontarolo R
    J Gastroenterol Hepatol; 2017 Apr; 32(4):749-755. PubMed ID: 27785825
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sofosbuvir-based treatment is safe and effective in patients with chronic hepatitis C infection and end stage renal disease: a case series.
    Singh T; Guirguis J; Anthony S; Rivas J; Hanouneh IA; Alkhouri N
    Liver Int; 2016 Jun; 36(6):802-6. PubMed ID: 26824848
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment.
    Okubo T; Atsukawa M; Tsubota A; Toyoda H; Shimada N; Abe H; Kato K; Hayama K; Arai T; Nakagawa-Iwashita A; Itokawa N; Kondo C; Kawamoto C; Iio E; Tanaka Y; Kumada T; Iwakiri K
    Hepatol Int; 2018 Mar; 12(2):133-142. PubMed ID: 29600429
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Successful treatment of sexually acquired acute HCV reinfection with ledipasvir/sofosbuvir in a HIV-infected patient.
    Sollima S; Antinori S; Torre A; Binda F; Giacomelli A; Milazzo L
    Int J STD AIDS; 2017 Jul; 28(8):838-840. PubMed ID: 28632109
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.